$1.05 Billion is the total value of First Light Asset Management, LLC's 75 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 36.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | Sell | PROTHENA CORPORATION PLC | $72,087,382 | -29.6% | 1,494,039 | -0.4% | 6.85% | -14.7% |
| OFIX | Sell | ORTHOFIX MED INC | $23,822,353 | -46.4% | 1,852,438 | -24.7% | 2.26% | -35.0% |
| INSM | Sell | INSMED INC | $16,250,597 | +19.3% | 643,588 | -0.3% | 1.54% | +44.6% |
| KRMD | Sell | KORU MEDICAL SYSTEMS INC | $14,275,699 | -21.9% | 5,287,296 | -0.2% | 1.36% | -5.4% |
| OMCL | Sell | OMNICELL INC | $13,928,350 | -41.2% | 309,244 | -3.9% | 1.32% | -28.8% |
| HALO | Sell | HALOZYME THERAPEUTICS INC | $11,977,075 | -43.2% | 313,536 | -46.3% | 1.14% | -31.1% |
| AXGN | Sell | AXOGEN INC | $9,625,660 | -46.6% | 1,925,132 | -2.5% | 0.91% | -35.3% |
| GMAB | Sell | GENMAB AS | $5,542,575 | -8.0% | 157,147 | -0.9% | 0.53% | +11.4% |
| Sell | MAXCYTE INC | $3,348,103 | -60.7% | 1,073,110 | -42.2% | 0.32% | -52.4% | |
| TECH | Sell | BIO TECHNE CORP | $2,238,768 | -17.3% | 32,889 | -0.9% | 0.21% | +0.5% |
| SLP | Sell | SIMULATIONS PLUS INC | $1,461,866 | -4.6% | 35,057 | -0.8% | 0.14% | +15.8% |
| CUTR | Sell | CUTERA INC | $1,445,270 | -83.3% | 240,078 | -57.9% | 0.14% | -79.8% |
| SYNH | Exit | SYNEOS HEALTH INC CLASS A | $0 | – | -5,736 | -100.0% | -0.02% | – |
| Exit | AKUMIN INC | $0 | – | -1,575,098 | -100.0% | -0.02% | – | |
| CSTL | Exit | CASTLE BIOSCIENCES INC | $0 | – | -160,126 | -100.0% | -0.17% | – |
| PFE | Exit | PFIZER INC | $0 | – | -140,235 | -100.0% | -0.40% | – |
| KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -101,259 | -100.0% | -0.93% | – |
| ABCM | Exit | ABCAM PLC | $0 | – | -710,745 | -100.0% | -1.36% | – |
| RETA | Exit | REATA PHARMACEUTICALS INC | $0 | – | -1,432,208 | -100.0% | -11.44% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.